Becoming a substantial holder
Filed with ASX · · 4 pages · English
Argenica Therapeutics Ltd on 6ix
Earlier from Argenica Therapeutics
- Quarterly Activities/Appendix 4C Cash Flow Report
- New Mechanism Findings Offer Insights Into Phase 2 Signal
- Notice of Annual General Meeting/Proxy Form
- Change of Director's Interest Notice
- AGM Date & Closing Date for Director Nominations
Follow Argenica Therapeutics into a list and get an email when it puts out news.
Follow Argenica Therapeutics